A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients' tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck.
TL;DR
- A novel mRNA cancer vaccine is significantly reducing tumor recurrence in melanoma patients.
- The study results were released by drugmakers Moderna and Merck.
- This vaccine represents a first-of-its-kind approach to cancer treatment.